While FOLFIRINOX or GEM + albumin-bound paclitaxel therapies are the most approved [31, 32], the addition of an iron chelator like DFX would contribute the tumour-proliferation-suppressive effects of this class of drug as well as its suppressive effects on the emergence of metastatic lesions during chemotherapy treatment, owing to the iron chelator’s ability to reduce Rac1 and Cdc42 activation. Here, CDC42 is linked to neoplasm.